Silence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Silence Therapeutics presented at the Morgan Stanley Global Healthcare Conference, highlighting its siRNA platform and pipeline progress. Its lead rare disease asset, SLN124 for Polycythemia Vera, demonstrated near 100% efficacy in maintaining hematocrit control and reducing phlebotomy in Phase 1, with Phase 2 data anticipated in H2 2026. The company's Phase III-ready zerlasiran, targeting the large Lp(a) market, achieved over 90% reduction and long durability, but Silence is actively seeking a partner for the significant cardiovascular outcomes trial. Additionally, Silence has a multi-target collaboration with AstraZeneca and reports a cash runway into 2028, supporting its pipeline development.

Analysis

Silence Therapeutics (SLN) is advancing a dual-pronged clinical strategy centered on its siRNA platform. The company is internally prioritizing its wholly-owned asset for Polycythemia Vera (PV), a rare blood cancer, which demonstrated compelling Phase 1 results, including nearly 100% efficacy in maintaining hematocrit control without phlebotomy in well-controlled patients. The upcoming Phase 2 data, expected in the second half of 2026, represents a primary value driver, with enrollment tracking to complete by year-end. A key potential differentiator for this program is a less frequent dosing schedule of every 6 or 12 weeks. In parallel, SLN's second lead asset, zerlasiran for elevated Lp(a), is Phase III-ready after showing potent and durable reductions of over 90%. Recognizing the substantial cost of a cardiovascular outcomes trial, estimated at over $300 million, management is actively pursuing a partnership to fund its progression, a prudent move that conserves capital but makes the asset's value contingent on a deal. The company's financial position is robust, with a stated cash runway of $114 million extending into 2028, which fully funds operations beyond the pivotal PV data readout and strengthens its negotiating position for the Lp(a) program.

Key Decisions for Investors

• The primary investment thesis rests on two distinct paths: the successful execution of the wholly-owned Polycythemia Vera program and the company's ability to secure a strategic partner for its Phase III-ready zerlasiran.
• Investors should closely monitor progress toward the key catalyst, which is the Phase 2 data for the PV program anticipated in H2 2026, as positive results could serve as a significant value inflection point.
• A partnership announcement for the zerlasiran Lp(a) program is a critical event to watch, as it would validate the asset and unlock its value without burdening Silence with the substantial ~$300M+ trial cost.
• The strong cash position with a runway into 2028 significantly de-risks the company's ability to reach the PV Phase 2 data readout, suggesting limited near-term dilution risk for current shareholders.